Skip to content
INDPIndaptus Therapeutics, Inc.

Earnings

When Indaptus Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

10-K due Mar 10 – 24

No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 5 filings.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 10 – 24

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$8.11M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$1.05MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 13, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$1.05M
    N/M
    EPS
    -$0.01
    N/M
    On September 8, 2026, the Company entered into a private placement for 20,338,974 shares of common stock and aggregate gross proceeds of approximately $24.0 million.
  2. Q2 2026Aug 13, 2026, before the openThe release4.6%by the close of Aug 13
    Revenue
    —
    —
    Net income
    -$1.79M
    N/M
    EPS
    -$0.02
    N/M
  3. Q1 2026May 15, 2026, before the openThe release9.9%by the close of May 15
    Revenue
    —
    —
    Net income
    -$2.54M
    N/M
    EPS
    -$0.23
    N/M
  4. Q4 2025Mar 17, 2026, after the close+5.1%by the close of Mar 18
    Revenue
    —
    —
    Net income
    -$8.11M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 13, 2026 · after-hoursNov 13, 202644 d10-Q——-$0.01—
Q2 2026Jun 30, 2026Aug 13, 2026 · pre-marketAug 13, 202644 d10-Q——-$0.024.6%
Q1 2026Mar 31, 2026May 15, 2026 · pre-marketMay 15, 202645 d10-Q——-$0.239.9%
FY 2025
Q4 2025derivedDec 31, 2025—Mar 17, 202676 d10-K———+5.1%
Q3 2025Sep 30, 2025Nov 12, 2025 · pre-marketNov 12, 202543 d10-Q——-$2.98+6.3%
Q2 2025Jun 30, 2025Aug 13, 2025 · pre-marketAug 13, 202544 d10-Q——-$9.090.7%
Q1 2025Mar 31, 2025May 14, 2025 · pre-marketMay 14, 202544 d10-Q——-$9.11+7.5%
FY 2024
Q4 2024derivedDec 31, 2024Mar 13, 2025 · pre-marketMar 13, 202572 d10-K———5.8%
Q3 2024Sep 30, 2024Nov 12, 2024 · pre-marketNov 12, 202443 d10-Q——-$9.041.7%
Q2 2024Jun 30, 2024Aug 12, 2024 · pre-marketAug 12, 202443 d10-Q——-$13.162.3%
Q1 2024Mar 31, 2024May 8, 2024 · pre-marketMay 8, 202438 d10-Q——-$0.45—
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 13, 2026051550
10-QAug 13, 2026037579
10-QMay 15, 2026023362
10-KMar 17, 2026010585
10-QNov 12, 2025021759
10-QAug 13, 2025023333
10-QMay 14, 2025010099
10-KMar 13, 2025010136
10-QNov 12, 2024044537
10-QAug 12, 2024031158

Provenance

ProvenanceData status and checks

Indaptus Therapeutics, Inc. · CIK 1857044 · Engraved from SEC EDGAR